Lifetime health and economic benefits of weight loss among obese persons

American Journal of Public Health

Volumn 89, Issue 10, 1999, Pages 1536-1542

  Oster, Gerry ^a   Thompson, David ^a   Edelsberg, John ^a   Bird, Amy P ^a   Colditz, Graham A ^b  

^a POLICY ANALYSIS INC PAI   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BODY MASS; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HEALTH STATUS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; STROKE; WEIGHT REDUCTION;

EID: 0032867655     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.89.10.1536     Document Type: Article

References (40)

1. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes. 1998;22:39-47.
2. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med. 1993;119(pt2):655-660.
3. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995;122:481-486.
4. Rimm EB, Stampfer MJ, Giovannucci E, et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol. 1995;141: 1117-1127.
5. MacMahon SW, Macdonald GJ, Bernstein L, Andrews G, Blacket RB. Comparison of weight reduction with metoprolol in treatment of hypertension in young overweight patients. Lancet. 1985;1(8440):1233-1236.
6. Wassertheil-Smoller S, Blaufox MD, Oberman AS, Langford HG, Davis BR, Wylie-Rosett J. The Trial of Antihypertensive Interventions and Management (TAIM) study: adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension. Arch Intern Med 1992;152:131-136.
7. Grimm RH Jr, Flack JM, Grandits GA, et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension. JAMA. 1996;275: 1549-1556.
8. Doar JWH, Wilde CE, Thompson ME, Sewell PFJ. Influence of treatment with diet alone on oral glucose-tolerance test and plasma sugar and insulin levels in patients with maturity-onset diabetes mellitus. Lancet. 1975;1(7919):1263-1266.
9. Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987;147:1749-1753.
10. Osterman J, Lin T, Nankin HR, Brown KA, Hornung CA. Serum cholesterol profiles during treatment of obese outpatients with a very low calorie diet. Effect of initial cholesterol levels. Int J Obes. 1992;16:49-58.
11. Pories WJ, MacDonald KG Jr, Morgan EJ, et al. Surgical treatment of obesity and its effect on diabetes: 10-y follow-up. Am J Clin Nutr. 1992;55(suppl):582S-585S.
12. Schotte DE, Stunkard AJ. The effects of weight reduction on blood pressure in 301 obese patients. Arch Intern Med. 1990;150:1701-1704.
13. Collins RW, Anderson JW. Medication cost savings associated with weight loss for obese non-insulin-dependent diabetic men and women. Prev Med. 1995;24:369-374.
14. Methods for voluntary weight loss and control: NIH Technology Assessment Conference Panel. Consensus Development Conference, 30 March to 1 April 1992. Ann Intern Med 1993; 119(pt 2): 764-770.
15. Rosenbaum M, Leibel RL, Hirsch J. Obesity. N Engl J Med 1997;337:396-407.
16. Comuzzie AG, Allison DB. The search for human obesity genes. Science. 1998;280: 1374-1377.
17. Woods SC, Seeley RJ, Porte D Jr, Schwarts MW. Signals that regulate food intake and energy homeostasis. Science. 1998;280: 1378-1383.
18. Oster G, Colditz GA, Kelly NL. The Economic Costs of Smoking and Benefits of Quitting. Boston, Mass: DC Heath; 1984.
19. Oster G, Colditz GA, Kelly NL. The economic costs of smoking and benefits of quitting for individual smokers. Prev Med. 1984;13: 377-389.
20. Oster G, Epstein AM. Primary prevention and coronary heart disease: the economic benefits of lowering serum cholesterol. Am J Public Health. 1986;76:647-656.
21. Wolf AM, Colditz GA. The cost of obesity: the US perspective. PharmacoEconomics. 1994; 5(suppl 1):34-37.
22. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB, for the Panel on Cost-Effectiveness in Health and Medicine. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1253-1258.
23. National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988-1994, NHANES III Adult, Exam, and Laboratory Data Files [book on CD-ROM]. Hyattsville, Md: Centers for Disease Control and Prevention; 1996. Public Use Data File Documentation 76200.
24. Rewers M, Hamman RF. Risk factors for non-insulin-dependent diabetes. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH, eds. Diabetes in America. 2nd ed. Bethesda, Md: National Institutes of Health; 1995:179-220.
25. Odell TW, Gregory MC. Cost of hypertension treatment. J Gen Intern Med. 1995;10:686-688.
26. Oster G, Borok GM, Menzin J, et al. Cholesterol-Reduction Intervention Study (CRIS): a randomized trial to assess effectiveness and costs in clinical practice. Arch Intern Med. 1996;156:731-739.
27. Huse DM, Oster G, Killen AR, Lacey MJ, Colditz GA. The economic costs of non-insulin-dependent diabetes mellitus. JAMA. 1989;262: 2708-2713.
28. Shurtleff D. Section 30: some characteristics related to the incidence of cardiovascular disease and death: Framingham study, 18-year follow-up. In: Kannel WB, Gordon T, eds. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Washington, DC: Dept of Health, Education and Welfare; 1974. DHEW publication (NIH) 74-599.
29. Petty GW, Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology. 1998;50: 208-216.
30. National Center for Health Statistics. Vital Statistics of the United States, 1992, Vol II: Mortality, Part B. Washington, DC: Public Health Service; 1996.
31. Oster G, Huse DM, Lacey MJ, Epstein AM. Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients. Stroke. 1994;25: 1149-1156.
32. Stampfer MJ, Maclure KM, Colditz GA, Manson JE, Willett WC. Risk of symptomatic gall-stones in women with severe obesity. Am J Clin Nutr. 1992;55:652-658.
33. Felson DT, Anderson JJ, Naimark A, Walker AM, Meenan RF. Obesity and knee osteoarthritis: The Framingham Study. Ann Intern Med. 1988;109:18-24.
34. Ballard-Barbash R, Swanson CA. Body weight: estimation of risk for breast and endometrial cancers. Am J Clin Nutr. 1996;63(suppl): 437S-441S.
35. Andres R, Muller DC, Sorkin JD. Long-term effects of change in body weight on all-cause mortality. Ann Intern Med. 1993;119(pt 2): 737-743.
36. Pamuk ER, Williamson DF, Serdula MK, Madans J, Byers TE. Weight loss and subsequent death in a cohort of US adults. Ann Intern Med. 1993;119(pt2):744-748.
37. Lissner L, Odell PM, D'Agostino RB, et al. Variability of body weight and health outcomes in the Framingham population. N Engl J Med. 1991;324:1839-1844.
38. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years. Am J Epidemiol. 1995;141:1128-1141.
39. Wadden TA. National Institutes of Health Technology Assessment Conference: treatment of obesity by moderate and severe caloric restriction: results of clinical research trials. Ann Intern Med. 1993;119(pt 2):688-693.
40. National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA. 1996;276:1907-1915.